AQR Capital Management
DSGN icon

AQR Capital Management’s Design Therapeutics DSGN Stock Holding History

AQR Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$276K Buy
25,957
+12,227
+89% +$124K ﹤0.01% 3445
2025
Q4 		$129K Buy
13,730
+66
+0.5% +$517 ﹤0.01% 3442
2025
Q3 		$103K Sell
13,664
-15,062
-52% -$75.4K ﹤0.01% 3367
2025
Q2 		$96.8K Sell
28,726
-3,014
-9% -$11.3K ﹤0.01% 3181
2025
Q1 		$123K Buy
31,740
+1,885
+6% +$8.99K ﹤0.01% 2976
2024
Q4 		$184K Buy
29,855
+19,071
+177% +$110K ﹤0.01% 2687
2024
Q3 		$58K Sell
10,784
-299
-3% -$1.41K ﹤0.01% 2698
2024
Q2 		$37.1K Sell
11,083
-665
-6% -$2.59K ﹤0.01% 2551
2024
Q1 		$47.3K Sell
11,748
-44,492
-79% -$119K ﹤0.01% 2377
2023
Q4 		$149K Buy
+56,240
New +$129K ﹤0.01% 2250

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AQR Capital Management's DSGN Position: Q1 2026 in Review

AQR Capital Management increased its Design Therapeutics (DSGN) stake by 89% in Q1 2026, buying an estimated $124K and bringing the position to 25,957 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #3445.

AQR Capital Management first reported a position in DSGN in Q4 2023 and has held it in 10 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • AQR Capital Management held 25,957 shares of Design Therapeutics worth $276K as of Q1 2026.
  • AQR Capital Management bought 12,227 Design Therapeutics shares in Q1 2026, an estimated $124K.
  • Design Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3445 holding.
  • AQR Capital Management first reported a position in Design Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.